Top 10 Companies in the (S)-1-Boc-3-Aminopiperidine (CAS 625471-18-3) Market (2026): Market Leaders Powering Global Pharmaceutical Synthesis

MARKET INSIGHTS

Global (S)-1-Boc-3-Aminopiperidine (CAS 625471-18-3) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 54.7 million by 2034, exhibiting a CAGR of 6.9% during the forecast period.

(S)-1-Boc-3-Aminopiperidine (CAS 625471-18-3) is a chiral piperidine derivative featuring a tert‑butoxycarbonyl (Boc) protecting group on the nitrogen at position 1 and a free amino group at position 3 in the (S)-configuration. This compound serves as a critical building block in pharmaceutical synthesis, particularly in the development of central nervous system (CNS) drugs, kinase inhibitors, and other biologically active small molecules. Its well‑defined stereochemistry makes it especially valuable in asymmetric synthesis and medicinal chemistry research.

The market is witnessing steady growth driven by rising demand for enantiomerically pure intermediates in drug discovery and development pipelines. The expanding global pharmaceutical industry, coupled with increasing investment in CNS therapeutics and oncology research, continues to support consumption of this compound. Furthermore, the growing adoption of fragment‑based drug design and the rise in contract research and manufacturing organization (CRMO) activities are amplifying procurement volumes. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, Combi‑Blocks, and AstaTech, among others, offering the compound across varying purity grades to meet diverse research and commercial manufacturing requirements.

(S)-1-Boc-3-Aminopiperidine (CAS 625471-18-3) Market – View in Detailed Research Report

Top 10 Companies in the (S)-1-Boc-3-Aminopiperidine Market

1. Sigma‑Aldrich (Merck KGaA)

   Headquarters: Darmstadt, Germany
   Key Offering: Pharmaceutical‑grade (S)-1‑Boc‑3‑aminopiperidine, analytical‑grade intermediates, custom synthesis services

   Sigma‑Aldrich has built a reputation for delivering high‑purity chiral intermediates to pharmaceutical R&D teams worldwide. Its extensive portfolio includes both standard grades and bespoke formulations tailored to specific synthetic routes. The company’s strong quality infrastructure ensures consistent enantiomeric excess and traceability, key factors for regulatory compliance.

   Sustainability Initiatives: Investment in green chemistry programs, reduction of hazardous solvent usage, and implementation of closed‑loop recycling for waste streams.

   • Global distribution network spanning 80+ countries
   • Dedicated technical support for chiral synthesis challenges
   • Integration of digital tools for batch tracking and documentation

2. TCI Chemicals

   Headquarters: Tokyo, Japan
   Key Offering: High‑purity (S)-1‑Boc‑3‑aminopiperidine, specialty reagents, custom synthesis

   TCI’s expertise lies in delivering fine chemicals with stringent purity specifications. The company serves both academic laboratories and industrial manufacturers, offering rapid turnaround for small‑batch orders and scalable production for larger volumes.

   Sustainability Initiatives: Adoption of solvent‑free reactions where feasible, use of renewable feedstocks, and certification under ISO 14001.

   • Strong presence in Asia‑Pacific and Europe
   • Robust quality assurance and batch‑release processes
   • Partnerships with academic institutions for early‑stage discovery projects

3. Combi‑Blocks Inc.

   Headquarters: Irvine, California, USA
   Key Offering: Modular chiral building blocks, (S)-1‑Boc‑3‑aminopiperidine, custom synthesis for medicinal chemistry

   Combi‑Blocks focuses on providing modular, high‑purity intermediates that accelerate lead optimization. The company’s platform emphasizes rapid library synthesis, enabling pharmaceutical companies to explore diverse substitution patterns efficiently.

   Sustainability Initiatives: Implementation of continuous flow processes to reduce waste, and use of biodegradable solvents.

   • Fast shipping times within North America
   • Dedicated library synthesis support for CROs
   • Transparent batch certification and documentation

4. AstaTech

   Headquarters: Shanghai, China
   Key Offering: High‑purity (S)-1‑Boc‑3‑aminopiperidine, analytical‑grade intermediates, custom synthesis services

   AstaTech’s production facilities are equipped with advanced chiral resolution technologies, enabling efficient scale‑up of enantiopure intermediates. The company serves a growing base of Chinese pharmaceutical manufacturers and international CROs.

   Sustainability Initiatives: Energy‑efficient reactors, waste‑minimization protocols, and compliance with ISO 9001.

   • Capacity for multi‑ton scale production
   • Strong emphasis on quality control and batch consistency
   • Strategic partnerships with local universities for research collaboration

5. Biosynth AG

   Headquarters: Basel, Switzerland
   Key Offering: Enantiopure (S)-1‑Boc‑3‑aminopiperidine, GMP‑grade intermediates, custom synthesis

   Biosynth leverages its GMP‑compliant facilities to supply pharmaceutical companies with regulatory‑ready intermediates. The firm’s portfolio includes a range of chiral building blocks tailored to complex synthetic routes.

   Sustainability Initiatives: Use of renewable energy sources for production, and implementation of waste‑reduction strategies.

   • Global customer base across Europe and North America
   • Strong technical support for process optimization
   • Adherence to ICH Q7 quality management standards

6. Enamine LLC

   Headquarters: Kyiv, Ukraine
   Key Offering: (S)-1‑Boc‑3‑aminopiperidine, custom synthesis, library building blocks

   Enamine’s platform focuses on rapid access to chiral intermediates for medicinal chemistry. The company’s robust R&D team develops new synthetic routes, enabling cost‑effective production of enantiopure compounds.

   Sustainability Initiatives: Commitment to reducing solvent usage, and adherence to green chemistry principles.

   • Strong presence in Eastern Europe and Russia
   • Fast turnaround for small‑batch orders
   • Collaborations with CROs for early‑stage discovery projects

7. Oakwood Products, Inc.

   Headquarters: New York, New York, USA
   Key Offering: High‑purity (S)-1‑Boc‑3‑aminopiperidine, analytical‑grade intermediates, custom synthesis

   Oakwood specializes in delivering fine chemicals with exceptional purity. The company’s facilities support both laboratory‑scale and pilot‑scale production, catering to a wide range of customer needs.

   Sustainability Initiatives: Energy‑efficient production processes, and waste‑reduction protocols.

   • Strong distribution network across North America
   • Dedicated technical support for chiral synthesis
   • Transparent batch release and documentation

8. Apollo Scientific Ltd.

   Headquarters: London, United Kingdom
   Key Offering: (S)-1‑Boc‑3‑aminopiperidine, custom synthesis, analytical services

   Apollo Scientific provides high‑quality chiral intermediates for pharmaceutical R&D. The firm’s expertise includes chiral resolution and asymmetric hydrogenation, allowing efficient scale‑up of enantiopure products.

   Sustainability Initiatives: Implementation of green chemistry practices, and compliance with ISO 14001.

   • Strong presence in the UK and European markets
   • Rapid turnaround for custom synthesis orders
   • Robust quality control and batch release procedures

9. Clearsynth Labs Ltd.

   Headquarters: Pune, India
   Key Offering: (S)-1‑Boc‑3‑aminopiperidine, biocatalytic synthesis, custom production

   Clearsynth focuses on biocatalytic routes to produce enantiopure intermediates, reducing energy consumption and solvent usage. The company serves both domestic Indian manufacturers and international CROs.

   Sustainability Initiatives: Use of enzyme‑based processes, and implementation of closed‑loop recycling.

   • Capacity for large‑scale production
   • Strong focus on biocatalysis and green chemistry
   • Partnerships with local universities for talent development

10. Hairui (Suzhou) Chemical Technology Co., Ltd.

    Headquarters: Suzhou, China
    Key Offering: (S)-1‑Boc‑3‑aminopiperidine, high‑purity intermediates, custom synthesis

    Hairui operates GMP‑compliant facilities and provides high‑purity chiral intermediates to pharmaceutical companies. The firm’s production capabilities support both pilot and commercial scale operations.

    Sustainability Initiatives: Energy‑efficient reactors, waste‑reduction protocols, and adherence to ISO 9001.

    • Strong presence in China and Asia‑Pacific
    • Comprehensive quality management system
    • Fast shipping and reliable supply chain

11. Shanghai Trustin Chemical Co., Ltd.

    Headquarters: Shanghai, China
    Key Offering: (S)-1‑Boc‑3‑aminopiperidine, GMP‑grade intermediates, custom synthesis

    Shanghai Trustin’s facilities are equipped with advanced chiral synthesis technologies, enabling efficient production of enantiopure intermediates for pharmaceutical applications.

    Sustainability Initiatives: Implementation of green chemistry practices and compliance with ISO 14001.

    • Capacity for multi‑ton scale production
    • Strong technical support for process development
    • Robust quality control and documentation

Download FREE Sample Report

Get Full Report

Market Outlook

The forecast period to 2034 is characterized by continued demand from pharmaceutical R&D, especially in CNS and oncology pipelines. The compound’s role as a stereochemically defined building block positions it as a cornerstone for advanced therapeutic development. Market participants anticipate steady growth driven by the need for high‑purity intermediates in both early‑stage discovery and late‑stage manufacturing.

Future Trends

• Expansion of biocatalytic synthesis routes to reduce cost and environmental impact.
• Increased collaboration between CROs and fine‑chemical suppliers to accelerate library synthesis.
• Greater emphasis on digital traceability and batch certification to meet regulatory demands.
• Growth of emerging market pharmaceutical ecosystems, particularly in Asia‑Pacific, driving regional demand.
• Adoption of green chemistry principles across the supply chain, influencing procurement decisions.